Do emerging antihypertensive therapies (PDE5i, sGCs, ERA, and AGTi) reduce cardiovascular and renal risks?
Mendelian randomization evidence supports the potential of PDE5i, sGCs, ERA, and AGTi in reducing cardiovascular and renal risks, warranting targeted clinical trials.
Our study highlights the potential of PDE5i, sGCs, ERA, and AGTi in reducing cardiovascular and renal risks. These findings underscore the necessity for targeted clinical trials to validate the efficacy and safety of these therapies.
Le et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: